Pasar al contenido principal

USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGENOMICA DEL CANCER Y LAS EPIDROGAS

PID2021-125282OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical Perspectives in Epitranscriptomics

  • Santos-Pujol, Eloy|||0000-0002-7788-6562
  • Quero-Dotor, Carlos|||0000-0002-3951-2287
  • Esteller, M|||0000-0003-4490-6093
Epitranscriptomics, the study of reversible and dynamic chemical marks on the RNA, is rapidly emerging as a pivotal field in post-transcriptional gene expression regulation. Increasing knowledge about epitranscriptomic landscapes implicated in disease pathogenesis proves an invaluable opportunity for the identification of epitranscriptomic biomarkers and the development of new potential therapeutic drugs. Hence, recent advances in the characterization of these marks and associated enzymes in both health and disease blaze a trail toward the use of epitranscriptomics approaches for clinical applications. Here, we review the latest studies to provide a wide and comprehensive perspective of clinical epitranscriptomics and emphasize its transformative potential in shaping future health care paradigms.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity

  • Sibai, Mustafa
  • Cervilla, Sergi
  • Grases, Daniela
  • Musulen, Eva
  • Lazcano, Rossana
  • Mo, Chia-Kuei
  • Davalos, Veronica
  • Fortian, Arola
  • Bernat, Adrià
  • Romeo, Margarita
  • Tokheim, Collin
  • Barretina, Jordi
  • Lazar, Alexander J.
  • Ding, Li
  • DUTRENEO Study Investigators
  • Grande, Enrique
  • Real, Francisco X.
  • Esteller, Manel
  • Bailey, Matthew H.
  • Porta-Pardo, Eduard
Tumors are complex ecosystems of interacting cell types. The concept of cancer hallmarks distills this complexity into underlying principles that govern tumor growth. Here, we explore the spatial distribution of cancer hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. We show that hallmark activity is spatially organized, with the cancer compartment contributing to the activity of seven out of 13 hallmarks, while the tumor microenvironment (TME) contributes to the activity of the rest. Additionally, we discover that genomic distance between tumor subclones correlates with differences in hallmark activity, even leading to clone-hallmark specialization. Finally, we demonstrate interdependent relationships between hallmarks at the junctions of TME and cancer compartments and how they relate to sensitivity to different neoadjuvant treatments in 33 bladder cancer patients from the DUTRENEO trial. In conclusion, our findings may improve our understanding of tumor ecology and help identify new drug biomarkers., This research was funded by MCIN/AEI/10.13039/501100011033 and the ERDF through PID2021-125282OB-I00, Generalitat de Catalunya (2021 SGR 01494) and the Sarah Jennifer Knott Foundation. The authors would like to thank Abel Gonzalez-Perez, Nuria Lopez-Bigas, and Eliezer Van Allen for their valuable feedback and the kind and generous patients who donated the samples that made this study possible. This work has been done as part of the PhD Programme in "Biochemistry, molecular biology and biomedicine" from Universitat Autonoma de Barcelona.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana
  • Llinàs-Arias, Pere
  • García-Prieto, Carlos A.
  • Noguera-Castells, Aleix
  • Pato, Miguel L.
  • Bueno-Costa, Alberto
  • Campillo-Marcos, Ignacio
  • Villanueva, Lorea
  • Oliver-Caldés, Aina
  • Cardus, Oriol
  • Salsench, Sergi V.
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa
  • Gutiérrez, Norma Carmen
  • Prósper, Felipe
  • Agirre, Xavier
  • Fernández de Larrea, Carlos
  • Martínez-López, Joaquín
  • Ferrer, Gerardo
  • Esteller, M.
The immune system is tightly regulated but plastic in humans. It has several lines of control, and its imbalance has severe consequences for our health. Epigenetics encompasses heritable biochemical changes of the chromatin that do not affect the DNA sequence [1]. Epigenetics is constituted of various levels of control, from structural changes (such as 3D chromatin arrangement) to small biochemical changes (such as DNA methylation) which affect gene expression1. In the context of immunity, epigenetics has been described to control important events for the system, such as cytotoxic cell activation or exhaustion [2]. Cytotoxic cell activation is critical for tumor clearance. To activate cytotoxicity, several interactions need to occur between the target cell and the immune cell. This group of interactions are commonly known as immune checkpoint (IC) events and determine the outcome of the synapse [3]. IC signals can be co-stimulatory or co-inhibitory, and depending on the amount of signals the immune cells receive, they will determine if the system activates or not. Several rounds of inhibitory signals may induce a senescent state or exhaustion phenotype on the cytotoxic cells [3]. One of these inhibitory markers is the poliovirus receptor (PVR, also known as CD155), which interacts mainly with the T cell immunoreceptor with Ig and ITIM domains (TIGIT) in cytotoxic cells [4]. Tumoral cells can use DNA methylation to regulate inhibition of co-stimulatory or overexpression of co-inhibitory markers [3]. Hematological malignancies present aberrant promoter methylation in several immune checkpoint genes and this dysregulation supports their tumorigenesis [5,6,7]. Multiple myeloma (MM) is a hematological malignancy characterized by the abnormal accumulation of plasma cells in the bone marrow. MM is notorious for its incurable nature and tendency for relapse, often becoming refractory to treatment [8]. This poses significant challenges, highlighting the urgent need for innovative therapies to enhance the prognosis of affected patients. This work aims to elucidate the epigenetic regulation in PVR, an immune checkpoint marker, and its relation to cytotoxic activation and immunotherapy sensitivity in the context of MM cells., We thank CERCA Programme / Generalitat de Catalunya for institutional support. The Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia has provided funding to ME (2017 SGR1080 and 2021 SGR01494). ME has also received funding from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033/EDRF ‘A way to make Europe’ (RTI2018-094049-B-I00 and PID2021-125282OB-I00), Cellex Foundation (CEL007) and “la Caixa” Foundation (LCF/PR/HR22/00732). LMV is a fellow of the Spanish Ministry of Science and Innovation grant under FPI contract no. PRE2019-089958. AOC received funding from the resident grant Ajut Clínic-La Pedrera 2019, granted by Hospital Clínic de Barcelona. CFL has received funding by grants from Asociación Española Contra el Cancer (AECC) LABAE21971FERN, the Instituto de Salud Carlos III (ISCIII) and co-founded by the European Union (FIS PI22/00647 and ICI19/00025), and 2021SGR01292 (AGAUR; Generalitat de Catalunya). GF is recipient of Ayuda Investigador AECC 2023 (INVES234765FERR), Fundación Científica AECC. We thank Bristol Myer Squibb for providing BMS-986207 anti-TIGIT Neutralizing Antibody and Genomics Unit of Josep Carreras Leukaemia Research Institute for their help and the advice provided., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The multiomics blueprint of the individual with the most extreme lifespan

  • Santos-Pujol, Eloy
  • Noguera-Castells, Aleix
  • Casado-Pelaez, Marta
  • García-Prieto, Carlos A
  • Vasallo, Claudia
  • Campillo-Marcos, Ignacio
  • Quero-Dotor, Carlos
  • Crespo-García, Eva
  • Bueno-Costa, Alberto
  • Setién, Fernando
  • Ferrer, Gerardo
  • Davalos, Veronica
  • Mereu, Elisabetta
  • Pluvinet, Raquel
  • Arribas, Carles
  • Torre, Carolina de la
  • Villavicencio, Francisco
  • Sumoy, Lauro
  • Granada, Isabel
  • Coles, Natalie S
  • Acha, Pamela
  • Solé, Francesc
  • Mallo, Mar
  • Mata, Caterina
  • Peregrina, Sara
  • Gabaldón, Toni
  • Llirós, Marc
  • Pujolassos, Meritxell
  • Carreras-Torres, Robert
  • Lluansí, Aleix
  • García-Gil, Librado Jesús
  • Aldeguer, Xavier
  • Samino, Sara
  • Torné, Pol
  • Ribalta, Josep
  • Guardiola, Montse
  • Amigó, Núria
  • Yanes, Oscar
  • Martínez, Paula
  • Sánchez-Vázquez, Raúl
  • Blasco, Maria A
  • Oviedo, Jose
  • Lemos, Bernardo
  • Rius-Bonet, Julia
  • Torrubiano, Marta
  • Massip-Salcedo, Marta
  • Khidir, Kamal A
  • Cao, Thong Huy
  • Quinn, Paulene A
  • Jones, Donald J L
  • Macip, Salvador
  • Brigos-Barril, Eva
  • Moldes, Mauricio
  • Barteri, Fabio
  • Muntané, Gerard
  • Laayouni, Hafid
  • Navarro, Arcadi
  • Esteller, Manel
Extreme human lifespan, exemplified by supercentenarians, presents a paradox in understanding aging: despite advanced age, they maintain relatively good health. To investigate this duality, we have performed a high-throughput multiomics study of the world's oldest living person, interrogating her genome, transcriptome, metabolome, proteome, microbiome, and epigenome, comparing the results with larger matched cohorts. The emerging picture highlights different pathways attributed to each process: the record-breaking advanced age is manifested by telomere attrition, abnormal B cell population, and clonal hematopoiesis, whereas absence of typical age-associated diseases is associated with rare European-population genetic variants, low inflammation levels, a rejuvenated bacteriome, and a younger epigenome. These findings provide a fresh look at human aging biology, suggesting biomarkers for healthy aging, and potential strategies to increase life expectancy. The extrapolation of our results to the general population will require larger cohorts and longitudinal prospective studies to design potential anti-aging interventions., We thank Yoana Veselinova for the drawing of the graphical abstract. Research in the M.E. group is funded by the CERCA Programme/Generalitat de Catalunya (MCIN/AEI/10.13039/501100011033/); the European Regional Development Fund, “A way to make Europe” ERDF (project PID2021-125282OB-I00 and PID2024-159192OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494); European Union under THRIVE grant agreement no. 101136622; “La Caixa” Research Foundation; and the Cellex Foundation (CEL007). E.S.-P. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPI contract no. PRE2022-105015. G.F. is a recipient of Ayuda Investigador AECC 2023 (INVES234765FERR), Fundación Científica AECC. C.Q.-D. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPU contract no. FPU22/01655. E.M.’s work in this publication was supported by the Ramón y Cajal fellowship RYC2021-032359-I, funded by the Spanish Ministry of Science and the Catalan Agency for Management of University and Research Grants (AGAUR, 2021 SGR 01586). Research in the A.N. group is supported by the I+D+i project PID2021-127792NB-I00, funded by MCIN/AEI/10.13039/501100011033 (FEDER Una manera de hacer Europa), and “Unidad de Excelencia María de Maeztu,” funded by the AEI (CEX2018-000792-M) and Departament de Recerca i Universitats de la Generalitat de Catalunya (GRC 2021 SGR 0467). Research in the R.C.-T.. group is funded by the Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01366). Research in the S.M. group was supported by the Instituto de Salud Carlos III (PI20/00328) and the M. C. Andreu Memorial Fund. J.R.-B. was supported by a doctoral grant from the Universitat Oberta de Catalunya. Research in the M.A.B. laboratory is funded by the European Union, project ERC-AvG Shelterins (GA 882385), Horizon 2020 Programme. The mass spectrometry work was supported by the John and Lucille Van Geest Foundation and the National Institute for Health and Care Research Leicester Biomedical Research Centre. M.E. is an ICREA Research Professor., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity

  • Sibai, Mustafa
  • Cervilla, Sergi
  • Grases, Daniela
  • Musulen, Eva
  • Lazcano, Rossana
  • Mo, Chia-Kuei
  • Davalos, Veronica
  • Fortian, Arola
  • Bernat, Adrià
  • Romeo, Margarita
  • Tokheim, Collin
  • Barretina, Jordi
  • Lazar, Alexander J.
  • Ding, Li
  • DUTRENEO Study Investigators
  • Grande, Enrique
  • Real, Francisco X.
  • Esteller, Manel
  • Bailey, Matthew H.
  • Porta-Pardo, Eduard
Tumors are complex ecosystems of interacting cell types. The concept of cancer hallmarks distills this complexity into underlying principles that govern tumor growth. Here, we explore the spatial distribution of cancer hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. We show that hallmark activity is spatially organized, with the cancer compartment contributing to the activity of seven out of 13 hallmarks, while the tumor microenvironment (TME) contributes to the activity of the rest. Additionally, we discover that genomic distance between tumor subclones correlates with differences in hallmark activity, even leading to clone-hallmark specialization. Finally, we demonstrate interdependent relationships between hallmarks at the junctions of TME and cancer compartments and how they relate to sensitivity to different neoadjuvant treatments in 33 bladder cancer patients from the DUTRENEO trial. In conclusion, our findings may improve our understanding of tumor ecology and help identify new drug biomarkers., This research was funded by MCIN/AEI/10.13039/501100011033 and the ERDF through PID2021-125282OB-I00, Generalitat de Catalunya (2021 SGR 01494) and the Sarah Jennifer Knott Foundation. The authors would like to thank Abel Gonzalez-Perez, Nuria Lopez-Bigas, and Eliezer Van Allen for their valuable feedback and the kind and generous patients who donated the samples that made this study possible. This work has been done as part of the PhD Programme in "Biochemistry, molecular biology and biomedicine" from Universitat Autonoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics

  • Janin, Maxime|||0000-0003-1013-4128
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M|||0000-0003-4490-6093
Most of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. Both regulations share similar mechanisms driven by DNA or RNA modifiers, namely writers, readers, and erasers; enzymes responsible of respectively introducing, recognizing, or removing the epigenetic or epitranscriptomic modifications. Epigenetic regulation is achieved by DNA methylation, histone modifications, non-coding RNAs, chromatin accessibility, and enhancer reprogramming. In parallel, regulation at RNA level, named epitranscriptomic, is driven by a wide diversity of chemical modifications in mostly all RNA molecules. These two-layer regulatory mechanisms are finely controlled in normal tissue, and dysregulations are associated with every hallmark of human cancer. In this review, we provide an overview of the current state of knowledge regarding epigenetic and epitranscriptomic alterations governing tumor metastasis, and compare pathways regulated at DNA or RNA levels to shed light on a possible epi-crosstalk in cancer metastasis. A deeper understanding on these mechanisms could have important clinical implications for the prevention of advanced malignancies and the management of the disseminated diseases. Additionally, as these epi-alterations can potentially be reversed by small molecules or inhibitors against epi-modifiers, novel therapeutic alternatives could be envisioned.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of the new EPIC DNA methylation microarray (900K EPIC v2) for high-throughput profiling of the human DNA methylome

  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Esteller, M|||0000-0003-4490-6093
DNA methylation, one of the best characterized epigenetic marks in the human genome, plays a pivotal role in gene transcription regulation and other biological processes in humans. On top of that, the DNA methylome undergoes profound changes in cancer and other disorders. However, large-scale and population-based studies are limited by high costs and the need for considerable expertise in data analysis for whole-genome bisulphite-sequencing methodologies. Following the success of the EPIC DNA methylation microarray, the newly developed Infinium HumanMethylationEPIC version 2.0 (900K EPIC v2) is now available. This new array contains more than 900,000 CpG probes covering the human genome and excluding masked probes from the previous version. The 900K EPIC v2 microarray adds more than 200,000 probes covering extra DNA cis-regulatory regions such as enhancers, super-enhancers and CTCF binding regions. Herein, we have technically and biologically validated the new methylation array to show its high reproducibility and consistency among technical replicates and with DNA extracted from FFPE tissue. In addition, we have hybridized primary normal and tumoural tissues and cancer cell lines from different sources and tested the robustness of the 900K EPIC v2 microarray when analysing the different DNA methylation profiles. The validation highlights the improvements offered by the new array and demonstrates the versatility of this updated tool for characterizing the DNA methylome in human health and disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

  • Ortiz-Barahona, Vanessa
  • Soler, Marta|||0000-0002-6656-957X
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Janin, Maxime|||0000-0003-1013-4128
  • Setien, Fernando|||0000-0002-4061-4635
  • Fernández-Rebollo, Irene
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre, Carolina
  • Guil, Sonia|||0000-0002-2257-3331
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Zhang, Pei Hong
  • Yang, Li
  • Guarnacci, Marco
  • Schumann, Ulrike
  • Preiss, Thomas
  • Balaseviciute, Ugne
  • Montal, Robert
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Esteller, M.|||0000-0003-4490-6093
Background: RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. Methods: Combining data mining and conventional experimental procedures, NSUN7 methylation and expression status was assessed in liver cancer cell lines and primary tumors. Loss-of-function and transfection-mediated recovery experiments coupled with RNA bisulfite sequencing and proteomics determined the activity of NSUN7 in downstream targets and drug sensitivity. Results: In this study, the initial screening for genetic and epigenetic defects of 5-methylcytosine RNA methyltransferases in transformed cell lines, identified that the NOL1/NOP2/Sun domain family member 7 (NSUN7) undergoes promoter CpG island hypermethylation-associated with transcriptional silencing in a cancer-specific manner. NSUN7 epigenetic inactivation was common in liver malignant cells and we coupled bisulfite conversion of cellular RNA with next-generation sequencing (bsRNA-seq) to find the RNA targets of this poorly characterized putative RNA methyltransferase. Using knock-out and restoration-of-function models, we observed that the mRNA of the coiled-coil domain containing 9B (CCDC9B) gene required NSUN7-mediated methylation for transcript stability. Most importantly, proteomic analyses determined that CCDC9B loss impaired protein levels of its partner, the MYC-regulator Influenza Virus NS1A Binding Protein (IVNS1ABP), creating sensitivity to bromodomain inhibitors in liver cancer cells exhibiting NSUN7 epigenetic silencing. The DNA methylation-associated loss of NSUN7 was also observed in primary liver tumors where it was associated with poor overall survival. Interestingly, NSUN7 unmethylated status was enriched in the immune active subclass of liver tumors. Conclusion: The 5-methylcytosine RNA methyltransferase NSUN7 undergoes epigenetic inactivation in liver cancer that prevents correct mRNA methylation. Furthermore, NSUN7 DNA methylation-associated silencing is associated with clinical outcome and distinct therapeutic vulnerability.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine, A multicentre retrospective study

  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Gattermann, Norbert
  • Wulfert, Michael
  • Chaparro, Lorea
  • Sole, F.|||0000-0002-3251-2161
  • Cabezón, Marta|||0000-0001-5122-7481
  • Jiménez-Lorenzo, María J.
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Zamora, Lurdes|||0000-0003-1713-7110
  • De Stefano, Alessia
  • Casalin, Irene
  • Finelli, C.
  • Follo, Matilde Y.
  • Esteller, M.|||0000-0003-4490-6093
Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.